Latuda (lurasidone) is expensive primarily because it’s still protected by multiple patents that block generic competitors from entering the market. A 30-day supply of brand-name Latuda runs roughly $4,400 at retail price, making it one of the costlier atypical antipsychotics available. The combination of patent protection, a lack of full generic competition, and the realities of how psychiatric drugs are priced in the U.S. all contribute to that number.
Patent Protection Keeps Generics Off the Market
The single biggest reason Latuda costs what it does is its patent portfolio. Sunovion Pharmaceuticals, the company that makes Latuda, holds not one but at least nine U.S. patents on the drug, with expiration dates staggered across the next several years. Some of these patents expired in early 2024, but others stretch as far out as November 2031. Several also carry pediatric exclusivity extensions, which add six extra months of protection beyond the listed expiration date.
This layered patent strategy is common among brand-name drugmakers. By securing patents on different aspects of a medication (the chemical compound itself, the formulation, the manufacturing process, specific uses), a company can extend its period of market exclusivity well beyond what a single patent would allow. The FDA did grant tentative approval to at least one generic version of lurasidone back in 2019, but “tentative” approval means the generic maker proved its product is equivalent to the brand. It does not mean the generic can actually be sold until the relevant patents expire or are successfully challenged in court.
Limited Generic Availability So Far
Some generic lurasidone has started reaching the market as certain patents have expired. The price range for generic lurasidone varies dramatically, from as low as $0.34 per tablet to as high as $36 per tablet, depending on the dose, pharmacy, and whether the supply chain has fully caught up. Compare that to brand-name Latuda at roughly $44 per tablet for the 40 mg dose.
Even when generics exist, prices don’t always plummet immediately. It typically takes multiple generic manufacturers entering the market before competition drives prices down significantly. In the early stages of generic availability, only one or two companies may have approval to sell, which limits the competitive pressure that creates real savings. Full, robust generic competition for lurasidone likely won’t arrive until the later patents expire in the mid-to-late 2020s or 2031.
How Drug Pricing Works for Psychiatric Medications
Latuda’s cost also reflects broader dynamics in how psychiatric medications are priced in the United States. Drugs for conditions like schizophrenia and bipolar depression treat chronic, ongoing illness. Patients often take them for years or even decades, which gives manufacturers a long revenue window per patient. Companies price accordingly, knowing that insurers and patients have limited alternatives if a specific drug works well for someone.
There’s also the matter of research and development costs. Bringing a psychiatric drug through clinical trials is expensive, partly because trials for mental health conditions tend to be large and lengthy. Sunovion spent years and significant capital getting Latuda approved for both schizophrenia (in 2010) and bipolar depression (in 2013). The company recoups that investment during the patent-protected period, which is why brand-name pricing stays high until generics arrive in force.
Insurance coverage adds another layer of complexity. Many insurance plans and pharmacy benefit managers place Latuda on higher formulary tiers, meaning patients face steeper copays or coinsurance. Some plans require prior authorization or step therapy, where you have to try cheaper alternatives first before the insurer will cover Latuda. If your plan covers it poorly, or you’re uninsured, you’re looking at the full retail price.
Ways to Reduce What You Pay
If you’re currently taking Latuda and struggling with the cost, a few options may help. The most straightforward is asking your pharmacist or prescriber whether generic lurasidone is available in your area and at your dose. Where generics are accessible, the savings can be substantial.
Sunovion offers a patient assistance program through Sunovion Support for people who are uninsured or underinsured. To qualify, your household income needs to be at or below 300% of the federal poverty level. The program provides up to a 90-day supply at a time, and you’ll need to submit a new application each year. For a household of one, 300% of the federal poverty level works out to roughly $45,000 per year in 2024, though the exact threshold shifts annually.
Prescription discount programs and coupons from sites like GoodRx or RxSaver can also reduce the out-of-pocket cost, particularly for the generic version. These won’t bring a $4,400 prescription down to nothing, but they can make a meaningful difference, especially if your insurance doesn’t cover the drug well. If cost is a barrier to staying on your medication, it’s worth raising directly with your prescriber, who may know about local programs or suggest a therapeutic alternative that your insurance covers more favorably.
Why Prices Vary So Much by Pharmacy
One frustrating reality with Latuda and its generic is that prices can differ enormously from one pharmacy to another, even within the same city. Retail pharmacies, mail-order pharmacies, and big-box store pharmacies all negotiate different wholesale prices. The same 30-day generic prescription might cost $10 at one pharmacy and over $1,000 at another. This isn’t a quirk specific to lurasidone. It’s a feature of the U.S. drug pricing system, where there is no single set price for most medications. Shopping around, checking discount tools, and considering mail-order options can all lead to lower prices for the same pill.